Coherent Market Insights added Latest Research Report titled ” Coronary Artery Disease Therapeutics Market, by Drug Type (Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Statin, and Others), by End User, and by Region (North America, Europe, Latin America, Asia Pacific, Middle East, and Africa) – Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026 ” to its Large Report database.
Coronary Artery Disease (CAD) is a medical condition developed due to damaged or diseased blood vessels, which supply blood, nutrients, and oxygen to the heart. Coronary heart disease is characterized by deposition of cholesterol plague in the arteries, which results into inflammation. Increasing deposition of plague eventually narrows the coronary arteries thereby decreasing the blood flow to the heart. Decrease of blood flow to the heart causes shortness of breath and chest pain leading to heart attack after complete blockage.
Coronary Artery Disease Therapeutics Market Drivers:-
The global market is expected to witness significant growth due to robust pipeline of drugs over the forecast period (2018-2026). For instance, hydroxychloroquine sulfate tablets sponsored by first affiliated hospital of Xi’an Jiaotong university, China is in the fourth phase of clinical trials, this drug suppresses symptoms of coronary artery disease. Atorvastatin sponsored by university health network, Toronto has completed phase two clinical trials in 2014, this drug reduces the risk of heart attack and myocardial infraction. PADMA 28 sponsored by University hospital Inselsiptal, Berne has completed phase 2 clinical trials in 2013, this drug has beneficial effect on arterial system, the autonomic nervous system and blood inflammatory markers in patients with coronary artery disease.
Key players operating in coronary artery disease therapeutics market include Astra Zeneca, Gilead, Novartis, Pfizer, Bayer, Merck & Co, Glaxo Smith Kline, and Mylan N.V.
Coronary Artery Disease Therapeutics Market Regional Analysis:-
North America is expected to hold dominant position in global coronary artery disease therapeutics market due to high prevalence of coronary artery disease. According to a survey conducted by Centers for disease control and prevention (CDC), in 2015, coronary heart disease kills more than 370,000 people annually in the U.S. out of which more than 92% had chest pain as a major symptom. According to a study conducted by American College of Cardiology, in 2017, more than 790000 people experience heart attack annually in the U.S. out of this around 47% people were reported to have hypertension and around 34% were reported to have high blood pressure.